Educational, research-use-only content. This article summarizes published scientific literature for informational purposes only and is not medical advice. The compounds discussed are supplied strictly for in-vitro laboratory research and are not approved for human or veterinary use.
What is cagrilintide?
Cagrilintide is a long-acting, lipidated analog of amylin — a hormone co-secreted with insulin by the pancreas that promotes satiety (a feeling of fullness). Natural amylin is difficult to develop as a drug because it readily forms amyloid fibrils; cagrilintide was engineered for stability and a long half-life to overcome this (Kruse et al., 2021).
What the clinical research examined
In a multicentre, randomized, double-blind phase 2 dose-finding trial in 706 adults with overweight or obesity (without diabetes), once-weekly cagrilintide produced dose-dependent reductions in body weight over 26 weeks — roughly 6–11% across doses versus about 3% with placebo, and at the highest dose modestly greater than the comparator liraglutide. The most common adverse events were gastrointestinal (nausea, constipation, diarrhoea) and injection-site reactions (Lau et al., 2021).
How it is thought to work
As an amylin-receptor agonist, cagrilintide is studied for its effects on satiety signaling and gastric emptying — a mechanism distinct from the GLP-1 pathway, which is why researchers have also examined it in combination with the GLP-1 analog semaglutide (Kruse et al., 2021).
The limits of the current evidence
- Cagrilintide is investigational: it has been studied in clinical trials but is not an approved medicine, and long-term safety and outcomes are still being established.
- The trial data come from a supervised clinical setting; they do not translate to unsupervised use, and the research material here is for laboratory use only.
References
According to PubMed:
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet. 2021. doi:10.1016/S0140-6736(21)01751-7
- Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021. doi:10.1021/acs.jmedchem.1c00565
